The Motley Fool points to a biosimilar approval target and supply fixes as the setup for wider margins while legacy drugs drag on growth.
Recap by typeshit. Full story at The Motley Fool on MSN.
The MFDS approval rests on SURPASS-CVOT, where Mounjaro matched Trulicity on heart events in 13,000+ patients but did not prove superior.
Inside Retail Asia looks at skincare and aesthetic treatments brands are building for facial volume loss after rapid weight loss.
The actor told an interviewer people can take Ozempic carefree, while stressing that nothing replaces actually working out.
CFO MV Narasimham says the company still expects to ship 6 to 7 million pens across 10 approved markets between November and March, with Canada taking most of them.
Investseekers shares fresh $NVO and $LLY script numbers pointing to ongoing pressure on Novo Nordisk's obesity treatments, with a note on Wegovy.
EMY reports the genetics company is moving away from drug discovery and toward prescribing GLP-1 weight loss medications.
Loading…